- Pegaspargase
-
Pegaspargase Systematic (IUPAC) name Pegylated E. coli L-asparagine amidohydrolase Clinical data AHFS/Drugs.com monograph MedlinePlus a695031 Pregnancy cat. ? Legal status ? Identifiers CAS number 130167-69-0 ATC code L01XX24 DrugBank BTD00079 UNII 7D96IR0PPM Chemical data Formula C1377H2208N382O442S17 Mol. mass 31731.9 g/mol (what is this?) (verify) Pegaspargase (pronounced /pəˈɡæspərɡeɪz/, trade name Oncaspar) is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation.
It is used in the treatment of acute lymphoblastic leukemia.[2][3]
References
- ^ "UNM Cancer Center". http://cancer.unm.edu/drug_dictionary.aspx?id=818. Retrieved 2007-08-28.[dead link]
- ^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
- ^ Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics 5 (6): 492–496.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.